Periodontal Treatment for Chronic Periodontitis With Rheumatoid Arthritis.
ACPA proteins
C-reactive proteins
Chronic periodontitis
Nonsurgical periodontal debridement
Rheumatoid arthritis
Rheumatoid factor
Journal
International dental journal
ISSN: 1875-595X
Titre abrégé: Int Dent J
Pays: England
ID NLM: 0374714
Informations de publication
Date de publication:
Dec 2022
Dec 2022
Historique:
received:
25
02
2022
revised:
18
04
2022
accepted:
20
04
2022
pubmed:
10
7
2022
medline:
18
11
2022
entrez:
9
7
2022
Statut:
ppublish
Résumé
History of rheumatoid arthritis (RA) increases risk of periodontal diseases. A pro-inflammatory condition noted in periodontitis is considered a trigger for RA. Thus, periodontal treatment aimed at attenuating the pro-inflammatory state could aid in potentially reducing the risk of RA. The objective of this research was to assess the effect of periodontal therapy on rheumatoid factor, Disease Activity Score-28, anti-citrullinated protein antibody, and C-reactive protein levels in patients with chronic periodontitis (CP) and RA. The sample consisted of 28 patients with CP and RA. The study was designed to be a double-blind, randomised controlled clinical study. The samples were randomly categorised to either the treatment group (n = 13) or the control group (n = 15). CP status (plaque index, bleeding on probing, probing pocket depth, clinical attachment loss), clinical rheumatologic status (Disease Activity Score), and biochemical status (C-reactive protein, anti-citrullinated protein antibody, and rheumatoid factor) were assessed at baseline and at follow-up at 8 to 12 weeks. The treatment group showed a highly statistically significant reduction in bleeding on probing (P < .005), probing pocket depth (P < .001), plaque index (P < .001), and C-reactive protein (P < .001); a gain in the clinical attachment loss (P < .001) and an improvement in Disease Activity Score-28 (P = .001) were observed at reassessment following nonsurgical periodontal treatment as compared to the control group. However, blood serum anti-citrullinated protein antibody (P = .002) and rheumatoid factor levels (P = .351) were found to increase from baseline to 8 to 12 weeks following subgingival scaling and root planing. Reduction of inflammation in the periodontium by nonsurgical periodontal therapy did not reduce anti-citrullinated protein antibody and rheumatoid factor levels. However, it has shown improvement in periodontal conditions, and remarkable changes were observed in the clinical Disease Activity Score and C-reactive protein levels of individuals with RA.
Sections du résumé
BACKGROUND
BACKGROUND
History of rheumatoid arthritis (RA) increases risk of periodontal diseases. A pro-inflammatory condition noted in periodontitis is considered a trigger for RA. Thus, periodontal treatment aimed at attenuating the pro-inflammatory state could aid in potentially reducing the risk of RA.
AIMS
OBJECTIVE
The objective of this research was to assess the effect of periodontal therapy on rheumatoid factor, Disease Activity Score-28, anti-citrullinated protein antibody, and C-reactive protein levels in patients with chronic periodontitis (CP) and RA.
MATERIALS AND METHODS
METHODS
The sample consisted of 28 patients with CP and RA. The study was designed to be a double-blind, randomised controlled clinical study. The samples were randomly categorised to either the treatment group (n = 13) or the control group (n = 15). CP status (plaque index, bleeding on probing, probing pocket depth, clinical attachment loss), clinical rheumatologic status (Disease Activity Score), and biochemical status (C-reactive protein, anti-citrullinated protein antibody, and rheumatoid factor) were assessed at baseline and at follow-up at 8 to 12 weeks.
RESULTS
RESULTS
The treatment group showed a highly statistically significant reduction in bleeding on probing (P < .005), probing pocket depth (P < .001), plaque index (P < .001), and C-reactive protein (P < .001); a gain in the clinical attachment loss (P < .001) and an improvement in Disease Activity Score-28 (P = .001) were observed at reassessment following nonsurgical periodontal treatment as compared to the control group. However, blood serum anti-citrullinated protein antibody (P = .002) and rheumatoid factor levels (P = .351) were found to increase from baseline to 8 to 12 weeks following subgingival scaling and root planing.
CONCLUSIONS
CONCLUSIONS
Reduction of inflammation in the periodontium by nonsurgical periodontal therapy did not reduce anti-citrullinated protein antibody and rheumatoid factor levels. However, it has shown improvement in periodontal conditions, and remarkable changes were observed in the clinical Disease Activity Score and C-reactive protein levels of individuals with RA.
Identifiants
pubmed: 35810012
pii: S0020-6539(22)00079-X
doi: 10.1016/j.identj.2022.04.008
pmc: PMC9676424
pii:
doi:
Substances chimiques
Rheumatoid Factor
9009-79-4
C-Reactive Protein
9007-41-4
Types de publication
Randomized Controlled Trial
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
832-838Informations de copyright
Copyright © 2022 The Authors. Published by Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Competing Interest None disclosed.
Références
Nat Rev Rheumatol. 2017 Oct;13(10):606-620
pubmed: 28835673
Medicine (Baltimore). 2014 Dec;93(27):e195
pubmed: 25501069
J Periodontol. 2013 Dec;84(12):e74-84
pubmed: 23701010
Autoimmun Rev. 2014 Nov;13(11):1114-20
pubmed: 25182207
Lancet. 2010 Sep 25;376(9746):1094-108
pubmed: 20870100
JAMA Netw Open. 2019 Jun 5;2(6):e195394
pubmed: 31173126
PLoS One. 2016 May 20;11(5):e0155956
pubmed: 27203435
J Periodontol. 2009 Apr;80(4):535-40
pubmed: 19335072
J Periodontal Res. 2016 Feb;51(1):103-11
pubmed: 26094771
Ann Periodontol. 1999 Dec;4(1):1-6
pubmed: 10863370
J Dent Res. 2005 Mar;84(3):269-73
pubmed: 15723869
Arthritis Rheum. 2010 Sep;62(9):2569-81
pubmed: 20872595
J Periodontol. 2000 Oct;71(10):1528-34
pubmed: 11063384
J Hum Reprod Sci. 2012 Jan;5(1):7-13
pubmed: 22870008
J Periodontol. 1967 Nov-Dec;38(6):Suppl:610-6
pubmed: 5237684
J Rheumatol. 2004 Feb;31(2):214-22
pubmed: 14760787
Odontology. 2006 Sep;94(1):10-21
pubmed: 16998613
J Dent Res. 2013 May;92(5):399-408
pubmed: 23525531
J Clin Periodontol. 2005 Apr;32(4):412-6
pubmed: 15811060
Rheumatology (Oxford). 2011 Jul;50(7):1189-93
pubmed: 21343168
Infect Immun. 1999 Jul;67(7):3248-56
pubmed: 10377098
Med Oral Patol Oral Cir Bucal. 2016 May 01;21(3):e349-54
pubmed: 26946202
J Clin Periodontol. 2013 Oct;40(10):907-15
pubmed: 23902301
J Clin Periodontol. 2011 Jun;38(6):532-41
pubmed: 21434962
Inflammation. 2004 Dec;28(6):311-8
pubmed: 16245073
J Periodontol. 2005 Nov;76(11 Suppl):2066-74
pubmed: 16277578
Arthritis Res Ther. 2013 Oct 01;15(5):R140
pubmed: 24286543
Curr Oral Health Rep. 2015;2:20-29
pubmed: 25657894
Infect Immun. 2000 Jun;68(6):3535-40
pubmed: 10816508
Braz Dent J. 2009;20(5):355-64
pubmed: 20126902
Ann Intern Med. 2007 Jun 5;146(11):797-808
pubmed: 17548411
Semin Arthritis Rheum. 2014 Oct;44(2):113-22
pubmed: 24880982
J Clin Immunol. 1991 May;11(3):132-42
pubmed: 1890163
Arthritis Rheum. 1988 Mar;31(3):315-24
pubmed: 3358796
Arthritis Rheum. 2004 Feb;50(2):380-6
pubmed: 14872479
J Clin Periodontol. 2009 Dec;36(12):1004-10
pubmed: 19929953
J Rheumatol. 1997 Aug;24(8):1477-85
pubmed: 9263138
Arthritis Rheum. 2011 Dec;63(12):3818-23
pubmed: 21953289
J Periodontol. 2012 Jun;83(6):773-9
pubmed: 22050546